Evidence map›Paper›PMID 38045405›Full record

ArticlebioRxiv : the preprint server for biology2023

Selective activation of intracellular β1AR using a spatially restricted antagonist.

Federica Liccardo, Johannes Morstein, Ting-Yu Lin, Julius Pampel, Kevan M Shokat, Roshanak Irannejad

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Federica LiccardoCardiovascular Research Institute, University of California, San Francisco, USA.ORCID 0000-0002-8449-9165
Johannes MorsteinDepartment of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, USA.ORCID 0000-0002-6940-288X
Ting-Yu LinCardiovascular Research Institute, University of California, San Francisco, USA.
Julius PampelDepartment of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, USA.
Kevan M ShokatDepartment of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, USA.ORCID 0000-0001-8590-7741
Roshanak IrannejadCardiovascular Research Institute, University of California, San Francisco, USA.ORCID 0000-0001-8702-2285

Funding

INVESTIGATION OF A NEWLY DISCOVERED ORGANELLE-BASED SIGNALING PARADIGMR35GM133521 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Roshanak Irannejad · 2019 to 2026
$3.3M
Inhibitors of the G protein GNAS which drives pancreatic tumorigenesisR01CA244550 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHOKAT, KEVAN M. · 2020 to 2024
$2.0M
Targeting Cancer at the Protein-Membrane InterfaceK99CA277358 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MORSTEIN, JOHANNES · 2023 to 2024
$326k
NCI NIH HHS K99 CA277358NCI NIH HHS R01 CA244550NIGMS NIH HHS R35 GM133521
6 · The paper itself

Abstract

G-protein-coupled receptors (GPCRs) regulate several physiological and pathological processes and represent the target of approximately 30% of FDA-approved drugs. GPCR-mediated signaling was thought to occur exclusively at the plasma membrane. However, recent studies have unveiled their presence and function at subcellular membrane compartments. There is a growing interest in studying compartmentalized signaling of GPCRs. This requires development of novel tools to separate GPCRs signaling at the plasma membrane from the ones initiated at intracellular compartments. We took advantage of the structural and pharmacological information available for β1-adrenergic receptor (β1AR), an exemplary GPCR that functions at subcellular compartments, and rationally designed spatially restricted antagonists. We generated a cell impermeable β1AR antagonist by conjugating a suitable pharmacophore to a sulfonate-containing fluorophore. This cell-impermeable antagonist only inhibited β1AR on the plasma membrane. In contrast, a cell permeable β1AR agonist containing a non-sulfonated fluorophore, efficiently inhibited both the plasma membrane and Golgi pools of β1ARs. Furthermore, the cell impermeable antagonist selectively inhibited the phosphorylation of downstream effectors of PKA proximal to the plasma membrane in adult cardiomyocytes while β1AR intracellular pool remained active. Our tools offer promising avenues for investigating compartmentalized β1AR signaling in various context, potentially advancing our understanding of β1AR-mediated cellular responses in health and disease. They also offer a general strategy to study compartmentalized signaling for other GPCRs in various biological systems.

Identifiers

PMID38045405
PMCPMC10690298

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.